A B ST R A C T The objectives of this investigation were: (a) to characterize the time and dose dependence of the effects of prostacyclin (PGI2) on renin release in healthy men; (b) to define whether PGI2-induced renin release is secondary to hemodynamic changes; (c) to determine the plasma and urine concentrations of 6-keto-PGFIa (the stable breakdown product of PGI2) associated with renin release induced by exogenous or pharmacologically enhanced endogenous PGI2. Intravenous PGI2 or 6-keto-PGFIa infusions at nominal rates of 2.5, 5.0, 10.0, and 20.0 ng/kg per min were performed in each of six normal human subjects; in three of them, PGI2 infusion was repeated after ,B-adrenergic blockade and cyclooxygenase inhibition.
INTRODUCTION
A large body of experimental as well as clinical evidence indicates that intrarenal metabolism of arachidonic acid via the cyclooxygenase pathway may participate in the control of renin release (1) (2) (3) . However, the precise nature of the arachidonate metabolite(s) involved remains questionable. Thus, although a va-riety of vasoactive prostaglandins (PG)' stimulate renin release, when infused systemically or intrarenally in several animal species and man, conflicting results have been reported on their effects on renin release from renal cortical slices or cortical cell suspensions (1) (2) (3) . The demonstration that rabbit cortical microsomes synthesize prostacyclin (PGI2) from arachidonic acid and PGG2 (4) , both of which were previously found to stimulate renin release from cortical slices (5) , has prompted the group of J. A. Oates to investigate the effects of PGI2 on renin release in this isolated system. They found PGI2 but not PGE2 to cause a time-dependent stimulation of renin release over the range of 0.1-10 gM (6) , and suggested that PGI2 is the metabolite of arachidonic acid, which mediates its effect on the secretion of renin in rabbit. We have recently reported preliminary evidence suggesting a similar role for PGI2 in man (7) . The aims of the present investigation were: (a) to characterize the time and dose dependence of the effects of exogenous PGI2 on plasma renin activity (PRA) in healthy men; (b) to define whether a secondary activation of the #B-adrenergic mechanism of renin release or endogenously released cyclooxygenase products possibly mediating other mechanisms of renin release were responsible for PGI2-induced PRA elevation; and (c) to determine the plasma and urine concentrations of 6-keto-PGF,a, (the stable breakdown product of PGI2) associated with renin release induced by exogenous or pharmacologically enhanced endogenous PGI2 (8) . For this purpose we have infused PGI2 or 6-keto-PGF,a, at four nominal rates into each of six normal human subjects and repeated PGI2 infusion in three of them after ,3-adrenergic blockade and cyclooxygenase inhibition. In addition, furosemide, which is known to stimulate renin release by causing an acute overall activation of the renal PG-system (9), was infused i.v. into six healthy women.
These studies demonstrate that PGI2-induced renin release is not mediated by adrenergic stimuli secondary to hemodynamic changes, and may represent a physiologic mechanism locally regulating juxtaglomerular function in man.
METHODS
Prostacyclin and 6-keto-prostaglandin Fla infusions. Six healthy male physicians (age: 27, 31, 34, 35, 43, and 50 yr; weight 63, 72, 65, 80, 80, and 72 kg) each consented to four consecutive 30-min PGI2 or 6-keto-PGF1,, infusions at nom-I Abbreviations used in this paper: MBP, mean blood pressure; PG, prostaglandin (used variously according to the identification of a given prostaglandin, i.e. PGE2 or PGI2); PRA, plasma renin activity; RIA, radioimmunoassay; TLC, thin-layer chromatography; GC/MS, gas chromatography/ mass spectrometry; 6-keto-PGF,a-LI, 6-keto-PGF,.-like immunoreactivity; TX, thromboxane.
inal rates of 2.5, 5.0, 10.0, and 20.0 ng/kg per min. In a given subject, PGI2 and 6-keto-PGFI, infusions were separated by intervals of at least 1 mo. After an overnight fast, the subjects remained fasting and in the recumbent position from -9 a.m. to 2 p.m. Intravenous catheters, one for infusion and one for sampling, were inserted into antecubital veins 60 min before the infusion. A sphygmomanometer cuff was placed around the left arm for arterial pressure recording. 0.5-1 mg of PGI2 sodium salt was dissolved in appropriate volumes of sterile glycine buffer pH 10.5 (both obtained from the Wellcome Research Laboratories, Beckenham, England, through the courtesy of Dr. S. Moncada) immediately before each study and cooled at 4°C. This solution was infused with a Harvard infusion apparatus (Harvard Apparatus Co., Inc., S. Natick, Mass.) at rates of 0.1-0.8 ml/min. A thermostatic jacket was built around the syringe in order to keep its temperature as close as possible to 4°C. The stability of PGI2 under these conditions was verified periodically by comparing the antiaggregatory activity of its solution taken at the end of each infusion period, with the activity of a freshly prepared standard. To obtain a sterile solution of 6-keto-PGFI,,, the corresponding amount of PGI2 was dissolved in sterile saline and boiled for 30 min; this concentrated solution was further diluted into an appropriate volume of glycine buffer, pH 10.5, and infused in an identical fashion to PGI2. Conversion of PGI2 into 6-keto-PGF,a was verified by assessment of loss of platelet antiaggregatory activity and radioimmunological determination of 6-keto-PGF,a content of this solution. No attempt was made at having the subjects blind as to the nature of the substance infused, in view of obvious and consistent subjective effects of PGI2, i.e. skin flushing, especially marked on face, neck, and palms, accompanied by a sensation of warmness in the same areas. No serious untoward effects occurred, although the highest infusion rate commonly caused restlessness and/or headache.
Blood samples (5-10 ml) were drawn (and blood pressure recorded) at 15-min intervals before and during each infusion and at more frequent intervals for 30 min after each infusion. Blood was promptly distributed into iced tubes containing EDTA (0.02 ml of a 5% solution per milliliter of blood). All tubes were promptly centrifuged in a refrigerated centrifuge and the supernates frozen for subsequent analysis.
Urine voided during 2 h preceding the infusion, at the end of it, and up to 24 h after the infusion was collected and immediately frozen. Both urine and plasma samples were kept at -20°C until the time of the assays.
Three of the same subjects gave their informed consent to repeating the PGI2 infusions after indomethacin and propranolol treatment in order to minimize the contribution of endogenous PG production and ,B-adrenergic receptors to renin release. The expected risk of enhanced vascular activity of infused PGI2 was fully discussed among the participating investigators, and appropriate measures were taken in order to secure immediate termination of any severe hypotensive effect. The highest infusion rate was reduced to 15 min for safety considerations. Propranolol (inderal, icpharma) was given according to a conventional schedule: 40 mg on day 1, 120 mg on day 2, 240 mg on days 3 and 4, and 80 mg on day 5, 2 h before the infusion. Indomethacin, (Indocid, Merck Sharp & Dohme Canada Ltd., Montreal, Quebec, Canada) was given on day 3 (100 mg), day 4 (150 mg), and day 5 (50 mg, 2 h before the infusion). The reason for a shorter indomethacin treatment lies in the possible attenuation of its inhibitory effect on renal PG synthesis despite sustained administration (10) . Blood and urine samples were obtained as described in the control study.
Furosemide studies. (Table I ). The least detectable concentration that can be measured with 95% confidence (i.e., 2 SD at zero) is 0.5 pg/ml. The immunological specificity of AS 1 is reported in Table II . 25-ml urine samples were extracted and subjected to silicic acid column chromatography before the assay as described (10) . The overall recovery was assessed by labeled as well as unlabeled 6-ketoPGFIe, and found to be identical to that of other urinary PG, i.e., -70% (10). Recovery yields were determined for each extraction-purification run by adding a known amount of [3H]PGFIe, and urinary PG concentrations were corrected accordingly. The silicic acid column eluates were assayed at a final dilution ranging from 1:60 to 1:300, depending upon the nature of the sample. Validation of RIA measurements was obtained by three independent criteria, i.e., comparison with other anti-6-keto-PGFie sera; characterization of the thin-layer chromatographic (TLC) pattern of distribution of the extracted 6-keto-PGFIe-like immunoreactivity (LI); comparison with gas-chromatography/mass spectrometry (GC/MS) determinations. Three additional anti-6-ketoPGFi, sera (which will be referred to as AS 2, AS 3, and AS The binding characteristics and immunological specificities of these antisera are described in Table I and II in comparison with AS 1. The TLC pattern of distribution of urinary 6-keto-PGFIe-LI was assessed with four different antisera, showing varying degrees of cross-reactivity with other structurally related compounds, as previously described for urinary PGE2 (10, 11) . For this purpose, purified extracts obtained from 24-h urine collections as well as from pooled 15-min samples obtained after furosemide injections were subjected to TLC using the ascending technique, as described in detail elsewhere (10) . The whole lanes corresponding to the chromatographed samples were then divided into 0.5-1-cm segments, the silica gel scraped off and eluted with methanol. Each eluate, from the origin to the solvent front, was then assayed for 6-keto-PGF1.-LI with four different antisera. For comparison with GC/MS determination, a 500-ml sample pooled from urine collections obtained from three subjects before PGI2 infusion was subjected to extraction and silicic acid column chromatography. 
RESULTS
Mean (± SD)%changes of mean blood pressure (MBP) and PRA induced by PGI2 or 6-keto-PGFIa infusion at each of the four nominal infusion rates are illustrated in Fig. 1 . PGI2 caused a dose-related decrease of MBP, fully reversible within 15 min after discontinuing the infusion. In addition, it caused a dose-dependent increase of PRA, which reached statistical significance only at 5 ng/kg per min, and was still significantly elevated 30 min after discontinuing the infusion. Changes in PRA and MBP correlated in a statistically significant fashion (r = 0.50, P < 0.01, n = 65). Heart rate increased progressively during the infusion, reaching a maximum during the 20-ng/kg per min stage (21 ±5%,P < 0.01). In contrast, 6-ketoPGFia infused into the same subjects at identical rates did not cause any statistically significant changes of the measured parameters. In addition to indicate that the stable breakdown product of PGI2 does not contribute to its biological effects to any significant extent, these results also demonstrate that the glycine buffer pH 10.5 used to dissolve PGI2 was virtually devoid of any effect on MBP or PRA.
Mean (±SD) plasma 6-keto-PGFIa concentrations measured before, during, and after PGI2 or 6-keto-PGF1, infusion, are illustrated in Fig. 2 rates of Na, PGE2, and 6-keto-PGFia before and during PGI2 or 6-keto-PGFIa infusion are shown in Table III , PGI2 but not 6-keto-PGFia, caused a statistically significant increase of urine flow and Na excretion rate. This was markedly attenuated in the three subjects receiving PGI2 infusion, after fB-adrenergic blockade and cyclooxygenase inhibition (not shown). Both PGI2 and 6-keto-PGFIa caused a marked elevation of the urinary 6-keto-PGFIa/PGE2 ratio from 0.52 to 9.5 and from 0.58 to 31.6, respectively. When calculated over the total amount of PGI2 or 6-keto-PGF1,a infused, percent recovery of unchanged urinary 6-keto-PGFia averaged 0.93 ± 0.34and 3.55 ± 1.12(Mean ± SD,P < 0.01), respectively. Approximately 95% of the recovered immunoreactive 6-keto-PGFIa was excreted within 2 h after the end of the infusion for both PGI2 and 6-keto-PGFIa.
The possible contribution of ,B-adrenergic stimuli and of secondary release of cyclooxygenase products of arachidonic acid metabolism to the observed PGI2-induced renin release was investigated by repeating PGI2 infusion in three subjects after pretreatment with a f,-adrenergic blocking agent, i.e. propranolol and a cyclooxygenase inhibitor, i.e. indomethacin. After this combined treatment, basal PRA averaged 0.2±0.09 ng/ml per h (mean±SD), as compared with 0.83±0. 25 of the previous experiment (P < 0.025). Diastolic blood pressure averaged 80±15 mm Hg as compared with 85±10 of the previous experiment (P = NS); heart rate averaged 52±5 beat/min as compared with 71±15 (P < 0.01) and indicated effective f3-adrenergic blockade.
The urinary excretion of PGE2 and 6-keto-PGFia averaged 14.2±6.3 and 6.1±3.5 ng/h before treatment and was reduced to 5.4±2.3 and 2.2±1.3, respectively, on day 3 of indomethacin treatment (mean±SD, P < 0.01 for both compounds), thus indicating effective cyclooxygenase inhibition. Mean (±SD) percent changes of MBP and PRA induced by PGI2 infusion, under control conditions and after propranolol and indomethacin treatment, are illustrated in Fig. 3 . Although this combined pharmacologic treatment significantly enhanced the hypotensive effect of infused PGI2 at higher infusion rates, it did not modify the dose-related pattern of PGI2-induced renin release to any significant extent. Persistence of ,3-adrenergic blockade throughout the experiment was further demonstrated by failure of heart rate to reach basal con- trol values, despite an appreciable drop of diastolic blood pressure (65 ± 7 beats/min at 55 ± 5 mm Hg at 10 ng/kg per min). The fate of plasma and urinary 6-keto-PGFia after the administration of a pharmacologic stimulus known to stimulate renin release via a cyclooxygenase-dependent mechanism (1-3) was investigated by infusing furosemide into six healthy women. Mean (±SE)urinary 6-keto-PGF1,, and sodium excretion, and PRA levels are illustrated in Fig. 4 . Furosemide caused a statistically significant increase of urinary 6-keto-PGFia and sodium excretion rates and PRA levels within the first 15 min. The excretion rate of 6-keto-PGFia increased three-to fourfold over basal levels, remained significantly elevated over a period of 60 min, and declined thereafter. PRA rose significantly after 15 min, and remained significantly elevated for the whole period of observation (3 h). 6-keto-PGF1,, remained undetectable (<7.5 pg/ml) in peripheral venous plasma throughout the study (not shown). Both the relative increase and time-course of urinary 6-keto-PGFIa excretion after furosemide injection were quite similar to the pattern of urinary PGE2, PGF2a, and TXB2, previously measured in the same subjects and described elsewhere (9) . When Although ample evidence exists to suggest that PGI2 has a direct stimulant effect on the renin release mechanism (1) (2) (3) , the possible contribution of hemodynamic effects and endogenously released PGI2 to the observed changes of PRA levels had to be verified in man. The quite similar dose dependence for the reduction of MBP and increase of PRA measured during PGI2 infusion makes it difficult to dissect out hemodynamically mediated from direct effects on renin release. However, the substantially unaltered increase of PRA levels observed during pharmacologic inhibition of 3-adrenergic activity and PG synthesis is strongly suggestive of a direct effect of PGI2 on the renin release mechanism. The possible contribution of a-adrenergic stimuli and of the macula densa mechanism to renin release should be minimized under these conditions, in view of their dependence on intact PG-synthesis (3). However, because the urinary excretion of 6-keto-PGFia and PGE2 (and presumably, the renal synthesis of PGI2 and PGE2) were incompletely suppressed by indomethacin treatment, a partial contri-bution of the residual cyclooxygenase activity of the kidney can not be ruled out. The results of the present study are consistent with the conclusion of Fr6lich et al. (18) that a cyclooxygenase-derived metabolite of arachidonic acid is a mediator of the nonadrenergic component of renin release in man. Gerber et al. (19) had previously provided evidence for such a direct effect in dogs, by showing an increase in renin production induced by intrarenal infusion of PGI2 at 10 ng/kg per min in renally denervated, f3-adrenergic blocked, indomethacin-treated dogs with unilateral nephrectomy.
To gain further insight into the participation of endogenous PGI2 formation in the mechanism of renin release, we investigated the effects of furosemide on the urinary excretion of 6-keto-PGFIa in healthy women. Both the relative increase and time-course of urinary 6-keto-PGFIa excretion following furosemide injection were quite similar to the excretory pattern of other cyclooxygenase-derived products of renal arachidonic acid metabolism (9), thus suggesting a common origin. PGI2 synthesis by human renal cortical and medullary microsomes has been reported recently by Hassid and Dunn (20) . When comparing the urinary excretion rates of 6-keto-PGF1a associated with furosemide-and PGI2-induced renin release, it becomes obvious that similar increases of PRA levels are associated with quite different elevations of urinary 6-keto-PGFIa. It seems likely that only a fraction of the infused PGI2 is necessary to cause renin release when enhanced precursor availability and/or diminished metabolism is induced within the kidney, by drugs or physiologic stimuli. The local nature of such activation is further supported by failure of furosemide to raise peripheral plasma levels of 6-keto-PGFIa. The possible contribution of enhanced PGE2 formation to renin release measured under these circumstances should also be considered, although it is questionable whether this compound has a direct effect on renin release (1-3) .
The identification of the immunoreactive material present in human urine as 6-keto-PGFIa was obtained by several independent criteria: (a) its identical immunochemical behaviour with authentic 6-keto-PGFIa; (b) its identical chromatographic behaviour on TLC with authentic 6-keto-PGFIa; (c) its detection by four different anti-6-keto-PGFia sera; and (d) its detection by GC/MS. The presence of 6-keto-PGFIa in human urine raises the question of its origin and significance. We had previously suggested that urinary 6-ketoPGFia might reflect a fraction of renal PGI2 escaping intrarenal metabolism (7) similarly to urinary PGE2 and PGF2a (21) and TXB2 (9) . Evidence in favor of a renal origin of urinary 6-keto-PGFIa is provided by its similar behaviour to other cyclooxygenase-derived products under a variety of pharmacologic and pathophysiologic conditions affecting renal arachidonic acid metabolism. These include: (a) furosemide injection (this study); (b) Bartter's syndrome (22) ; and (c) indomethacin (22) or sulindac (23) administration in healthy women as well as in patients with Bartter's syndrome. Evidence against a renal origin of urinary 6-keto-PGF,a is provided by the recovery of significant amounts of this compound following PGI2 infusion, as demonstrated by Rosenkranz et al. (24) and confirmed in our study. It should, however, be pointed out that both studies were carried out by infusing pharmacologic doses of PGI2, 25-200 times higher than the maximal estimates of endogenous secretion rates.2
In this study, no 6-keto-PGFia could be detected in peripheral venous plasma, under basal conditions, in contrast to previous reports of circulating 6-ketoPGFIa levels as detected by RIA (25) or GC/MS (26) . In view of rapid disappearance of 6-keto-PGFIa from the circulation, demonstrated in this study, with a behavior quite similar to that of PGE, (27) , and relatively low rate of entry of endogenous PGI2 into the circulation2, it is not surprising to find undetectable levels of this compound in peripheral venous blood. Furosemide-induced renal PGI2 release, as detected by increased urinary 6-keto-PGFIa excretion, was not associated with circulating levels of this compound. A plasma metabolite with a longer t1/2, such as 13,14-dihydro-6,15-diketo-PGFia, would probably give some long term indication as to the amounts of PGI2 released in man (28) .
Although our findings clearly demonstrate that the stable hydrolysis product of PGI2, 6-keto-PGF1l, does not contribute to the observed changes of renin release to any measurable extent, they do not allow us to exclide the possibility that enzymatic conversion of PGI2 to a chemically stable and biologically active compound, such as 6-keto-PGE, (29) , might contribute to some of its effects.
We conclude that in human subjects: (a) PGI2-induced renin release occurs with a dose and time dependence similar to its reported platelet effects; (b) PGI2-induced renin release is not mediated by adrenergic stimuli or cyclooxygenase-dependent mechanisms secondary to hemodynamic changes; (c) furosemide-induced renin release is associated with increased renal PGI2 formation; and (d) PGI2 appears to act as a local modulator rather than a circulating hormone in controlling juxtaglomerular function.
